Brief: Galmed Announces First Time Results In Prostate Oncology Studies Aramchol Demonstrates 3-4 Fold Increase In Cell Death Compared To Enzalutamide Alone In Prostate Cancer Models
17/08/2026 14:23
BRIEF-Galmed Announces First Time Results In Prostate Oncology Studies Aramchol Demonstrates 3-4 Fold Increase In Cell Death Compared To Enzalutamide Alone In Prostate Cancer Models Aug 17 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:
GALMED ANNOUNCES FIRST TIME RESULTS IN PROSTATE ONCOLOGY STUDIES: ARAMCHOL DEMONSTRATES 3-4 FOLD INCREASE IN CELL DEATH COMPARED TO ENZALUTAMIDE (XTANDI®) ALONE IN PROSTATE CANCER MODELS
Source text: ID:nPn6skdQba
Further company coverage: GLMD.O
((Reuters.Briefs@thomsonreuters.com;))